Bio-Techne Corporation

NasdaqGS TECH

Bio-Techne Corporation EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD 236.58 M

Bio-Techne Corporation EBIT is USD 236.58 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -19.58% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Bio-Techne Corporation EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 294.18 M, a 7.34% change year over year.
  • Bio-Techne Corporation EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 274.07 M, a 35.29% change year over year.
  • Bio-Techne Corporation EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 202.58 M, a 3.07% change year over year.
  • Bio-Techne Corporation EBIT for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 196.55 M, a 30.17% change year over year.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
Loading...
NasdaqGS: TECH

Bio-Techne Corporation

CEO Mr. Kim Kelderman
IPO Date Feb. 9, 1989
Location United States
Headquarters 614 McKinley Place N.E.
Employees 3,100
Sector Health Care
Industries
Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Similar companies

LQDA

Liquidia Corporation

USD 11.36

-3.40%

LEGN

Legend Biotech Corporation

USD 31.64

-2.65%

UTHR

United Therapeutics Corporation

USD 364.70

0.50%

VTYX

Ventyx Biosciences, Inc.

USD 1.94

-0.51%

AKRO

Akero Therapeutics, Inc.

USD 21.87

-3.36%

APLS

Apellis Pharmaceuticals, Inc.

USD 27.69

-3.15%

PCVX

Vaxcyte, Inc.

USD 78.14

-3.73%

ASND

Ascendis Pharma A/S

USD 131.57

-1.84%

ALNY

Alnylam Pharmaceuticals, Inc.

USD 240.51

-6.88%

EXEL

Exelixis, Inc.

USD 35.65

0.99%

BMRN

BioMarin Pharmaceutical Inc.

USD 63.81

-4.75%

TVTX

Travere Therapeutics, Inc.

USD 17.07

-8.18%

HALO

Halozyme Therapeutics, Inc.

USD 53.83

-0.57%

BPMC

Blueprint Medicines Corporation

USD 102.56

-0.77%

REPL

Replimune Group, Inc.

USD 10.49

-3.67%

NUVL

Nuvalent, Inc.

USD 72.39

0.74%

StockViz Staff

January 15, 2025

Any question? Send us an email